2020-06-300001704292--12-312020Q2false00017042922020-01-012020-06-300001704292zlab:HanhuiPharmaceuticalsIncorporationMemberzlab:ExclusivePromotionAgreementMember2020-06-300001704292country:CN2019-01-012019-12-310001704292srt:MinimumMember2019-01-012019-06-300001704292srt:MaximumMember2019-01-012019-06-300001704292zlab:DeferredRevenueNonCurrentMember2020-01-012020-06-300001704292us-gaap:OtherIncomeMember2020-01-012020-06-300001704292zlab:DeferredRevenueNonCurrentMember2019-01-012019-12-310001704292us-gaap:OtherIncomeMember2019-01-012019-06-300001704292zlab:ZaiLabShanghaiCompanyLimitedMember2020-01-012020-06-300001704292zlab:TurningPointTherapeuticsIncMemberus-gaap:SubsequentEventMember2020-07-012020-07-310001704292zlab:HanhuiPharmaceuticalsIncorporationMemberzlab:ExclusivePromotionAgreementMember2020-04-012020-04-300001704292zlab:HanhuiPharmaceuticalsIncorporationMemberzlab:ExclusivePromotionAgreementMember2020-03-012020-03-310001704292zlab:RegeneronPharmaceuticalsIncorporationMember2020-04-012020-04-300001704292zlab:IncyteMember2019-07-012019-07-310001704292zlab:MacroGenicsIncMember2018-11-012018-11-300001704292zlab:CrescendoBiologicsLtdMember2018-05-012018-05-310001704292zlab:EntasisTherapeuticsHoldingsIncorporationMember2018-04-012018-04-300001704292zlab:FivePrimeTherapeuticsIncorporationMember2017-12-012017-12-310001704292zlab:ParatekBermudaLimitedMember2017-04-012017-04-300001704292zlab:TesaroMember2016-09-012016-09-300001704292zlab:TurningPointTherapeuticsIncMembersrt:MaximumMemberus-gaap:SubsequentEventMember2020-07-012020-07-310001704292zlab:RegeneronPharmaceuticalsIncorporationMembersrt:MaximumMember2020-04-012020-04-300001704292zlab:IncyteMembersrt:MaximumMember2019-07-012019-07-310001704292zlab:DecipheraMembersrt:MaximumMember2019-06-012019-06-300001704292zlab:MacroGenicsIncMembersrt:MaximumMember2018-11-012018-11-300001704292zlab:NovocureLimitedMembersrt:MaximumMember2018-09-012018-09-300001704292zlab:CrescendoBiologicsLtdMembersrt:MaximumMember2018-05-012018-05-310001704292zlab:EntasisTherapeuticsHoldingsIncorporationMembersrt:MaximumMember2018-04-012018-04-300001704292zlab:FivePrimeTherapeuticsIncorporationMembersrt:MaximumMember2017-12-012017-12-310001704292zlab:ParatekBermudaLimitedMembersrt:MaximumMember2017-04-012017-04-300001704292zlab:TesaroMembersrt:MaximumMember2016-09-012016-09-300001704292zlab:DecipheraMember2019-06-012019-06-300001704292zlab:NovocureLimitedMember2018-09-012018-09-300001704292zlab:ZaiLabUSLLCMember2020-01-012020-06-300001704292zlab:ZaiLabSuzhouCompanyLimitedMember2020-01-012020-06-300001704292zlab:ZaiLabShanghaiCompanyLimitedMember2020-01-012020-06-300001704292zlab:ZaiLabInternationalTradingShanghaiCompanyLimitedMember2020-01-012020-06-300001704292zlab:ZaiLabHongKongLimitedMember2020-01-012020-06-300001704292zlab:ZaiLabAUSTPtyLtdMember2020-01-012020-06-300001704292zlab:ZaiBiopharmaceuticalSuzhouCompanyLimitedMember2020-01-012020-06-300001704292us-gaap:CommonStockMember2020-01-012020-06-300001704292us-gaap:CommonStockMember2019-01-012019-06-300001704292us-gaap:RetainedEarningsMember2020-06-300001704292us-gaap:AdditionalPaidInCapitalMember2020-06-300001704292us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-300001704292us-gaap:RetainedEarningsMember2019-12-310001704292us-gaap:AdditionalPaidInCapitalMember2019-12-310001704292us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001704292us-gaap:RetainedEarningsMember2019-06-300001704292us-gaap:AdditionalPaidInCapitalMember2019-06-300001704292us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-06-300001704292us-gaap:RetainedEarningsMember2018-12-310001704292us-gaap:AdditionalPaidInCapitalMember2018-12-310001704292us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-3100017042922019-01-012019-12-3100017042922018-01-012018-12-3100017042922015-03-050001704292zlab:IndependentDirectorsMemberzlab:NonVestedRestrictedSharesMember2020-01-012020-06-300001704292us-gaap:ManagementServiceMemberzlab:NonVestedRestrictedSharesMember2020-01-012020-06-300001704292zlab:IndependentDirectorsMemberzlab:NonVestedRestrictedSharesMember2019-01-012019-12-310001704292us-gaap:ManagementServiceMemberzlab:NonVestedRestrictedSharesMember2019-01-012019-12-310001704292zlab:ManagementEmployeesAndIndividualAdvisorsMemberzlab:TwoThousandSeventeenEquityIncentivePlanMember2020-01-012020-06-300001704292zlab:ManagementEmployeesAndIndividualAdvisorsMemberzlab:TwoThousandSeventeenEquityIncentivePlanMember2019-01-012019-12-310001704292zlab:NonVestedRestrictedSharesMember2019-12-310001704292srt:MinimumMemberzlab:ManagementEmployeesAndIndividualAdvisorsMemberzlab:TwoThousandSeventeenEquityIncentivePlanMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2020-01-012020-06-300001704292srt:MaximumMemberzlab:ManagementEmployeesAndIndividualAdvisorsMemberzlab:TwoThousandSeventeenEquityIncentivePlanMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2020-01-012020-06-300001704292us-gaap:ManagementServiceMemberzlab:NonVestedRestrictedSharesMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2020-01-012020-06-300001704292srt:MinimumMemberzlab:ManagementEmployeesAndIndividualAdvisorsMemberzlab:TwoThousandSeventeenEquityIncentivePlanMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2019-01-012019-12-310001704292srt:MaximumMemberzlab:ManagementEmployeesAndIndividualAdvisorsMemberzlab:TwoThousandSeventeenEquityIncentivePlanMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2019-01-012019-12-310001704292us-gaap:ManagementServiceMemberzlab:NonVestedRestrictedSharesMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2019-01-012019-12-310001704292srt:MinimumMemberzlab:ManagementEmployeesAndIndividualAdvisorsMemberzlab:TwoThousandSeventeenEquityIncentivePlanMember2020-01-012020-06-300001704292srt:MaximumMemberzlab:ManagementEmployeesAndIndividualAdvisorsMemberzlab:TwoThousandSeventeenEquityIncentivePlanMember2020-01-012020-06-300001704292srt:MinimumMemberzlab:ManagementEmployeesAndIndividualAdvisorsMemberzlab:TwoThousandSeventeenEquityIncentivePlanMember2019-01-012019-12-310001704292srt:MaximumMemberzlab:ManagementEmployeesAndIndividualAdvisorsMemberzlab:TwoThousandSeventeenEquityIncentivePlanMember2019-01-012019-12-310001704292zlab:CustomerEMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-06-300001704292zlab:ZejulaMember2020-01-012020-06-300001704292zlab:OptuneMember2020-01-012020-06-300001704292zlab:CustomerMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-06-300001704292zlab:CustomerDMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-06-300001704292zlab:ZejulaMember2019-01-012019-06-300001704292zlab:OptuneMember2019-01-012019-06-300001704292zlab:ResearchAndDevelopmentExpensesMemberus-gaap:SupplierConcentrationRiskMemberzlab:SupplierEMember2020-01-012020-06-300001704292zlab:ResearchAndDevelopmentExpensesMemberus-gaap:SupplierConcentrationRiskMemberzlab:SupplierBMember2020-01-012020-06-300001704292zlab:ResearchAndDevelopmentExpensesMemberus-gaap:SupplierConcentrationRiskMemberzlab:SupplierCMember2019-01-012019-06-300001704292zlab:RelatedPartyTransactionResearchAndDevelopmentExpensesMemberus-gaap:LimitedLiabilityCompanyMember2020-01-012020-06-300001704292zlab:RelatedPartyTransactionResearchAndDevelopmentExpensesMemberus-gaap:LimitedLiabilityCompanyMember2019-01-012019-06-300001704292us-gaap:LimitedLiabilityCompanyMember2020-01-012020-06-300001704292us-gaap:PropertyPlantAndEquipmentMember2020-06-300001704292zlab:LaboratoryEquipmentMember2020-01-012020-06-300001704292zlab:ElectronicEquipmentMember2020-01-012020-06-300001704292us-gaap:VehiclesMember2020-01-012020-06-300001704292us-gaap:OfficeEquipmentMember2020-01-012020-06-300001704292us-gaap:ManufacturingFacilityMember2020-01-012020-06-300001704292zlab:ManufacturingEquipmentMember2020-06-300001704292zlab:LaboratoryEquipmentMember2020-06-300001704292zlab:ElectronicEquipmentMember2020-06-300001704292us-gaap:VehiclesMember2020-06-300001704292us-gaap:OfficeEquipmentMember2020-06-300001704292us-gaap:LeaseholdImprovementsMember2020-06-300001704292us-gaap:ConstructionInProgressMember2020-06-300001704292zlab:ManufacturingEquipmentMember2019-12-310001704292zlab:LaboratoryEquipmentMember2019-12-310001704292zlab:ElectronicEquipmentMember2019-12-310001704292us-gaap:VehiclesMember2019-12-310001704292us-gaap:OfficeEquipmentMember2019-12-310001704292us-gaap:LeaseholdImprovementsMember2019-12-310001704292us-gaap:ConstructionInProgressMember2019-12-310001704292us-gaap:LeaseholdImprovementsMember2020-01-012020-06-300001704292zlab:ZaiLabSuzhouCompanyLimitedMember2019-07-012019-12-310001704292zlab:ZaiLabSuzhouCompanyLimitedMember2019-01-012019-06-300001704292zlab:ZaiBiopharmaceuticalSuzhouCompanyLimitedMember2019-01-012019-06-300001704292us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-06-300001704292us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-06-300001704292us-gaap:LatestTaxYearMember2020-01-012020-06-300001704292us-gaap:EarliestTaxYearMember2020-01-012020-06-300001704292us-gaap:RetainedEarningsMember2020-01-012020-06-300001704292us-gaap:RetainedEarningsMember2019-01-012019-06-300001704292zlab:ZaiBiopharmaceuticalSuzhouCompanyLimitedMember2018-12-120001704292zlab:ZaiLabSuzhouCompanyLimitedMember2018-06-250001704292zlab:ZaiLabSuzhouCompanyLimitedMember2020-06-300001704292zlab:ZaiBiopharmaceuticalSuzhouCompanyLimitedMember2020-06-300001704292zlab:ZaiBiopharmaceuticalSuzhouCompanyLimitedMember2018-12-122018-12-120001704292zlab:ZaiLabSuzhouCompanyLimitedMember2018-06-252018-06-250001704292zlab:ZaiLabHongKongLimitedMember2020-01-012020-06-300001704292zlab:JINGMedicineTechnologyShanghaiLtdMember2020-01-012020-06-300001704292zlab:JINGMedicineTechnologyShanghaiLtdMember2019-01-012019-06-300001704292country:US2020-01-012020-06-300001704292country:KY2020-01-012020-06-300001704292country:HK2020-01-012020-06-300001704292country:AU2020-01-012020-06-300001704292zlab:ZaiLabUSLLCMember2019-01-012019-06-300001704292zlab:ZaiLabAUSTPtyLtdMember2019-01-012019-06-300001704292country:US2019-01-012019-06-300001704292country:KY2019-01-012019-06-300001704292country:HK2019-01-012019-06-300001704292country:AU2019-01-012019-06-300001704292srt:MinimumMember2020-01-012020-06-300001704292srt:MaximumMember2020-01-012020-06-300001704292zlab:JINGMedicineTechnologyShanghaiLtdMember2017-06-300001704292us-gaap:EmployeeStockOptionMember2020-06-300001704292zlab:NonVestedRestrictedSharesMember2020-06-300001704292zlab:ZaiLabHongKongLimitedMemberzlab:ProfitsOfFirstTwoMillionMember2020-01-012020-06-300001704292zlab:ZaiLabHongKongLimitedMemberzlab:ProfitsOfAboveTwoMillionMember2020-01-012020-06-300001704292zlab:ZaiLabUSLLCMember2020-01-012020-06-300001704292zlab:ZaiLabSuzhouCompanyLimitedMember2020-01-012020-06-300001704292zlab:ZaiLabInternationalTradingShanghaiCompanyLimitedMember2020-01-012020-06-300001704292zlab:ZaiLabAUSTPtyLtdMember2020-01-012020-06-300001704292zlab:ZaiBiopharmaceuticalSuzhouCompanyLimitedMember2020-01-012020-06-300001704292country:CN2020-01-012020-06-300001704292country:CN2019-01-012019-06-300001704292zlab:ResearchAndDevelopmentExpensesMemberus-gaap:SupplierConcentrationRiskMember2020-01-012020-06-300001704292us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-06-300001704292us-gaap:CashAndCashEquivalentsMemberzlab:ForeignCurrencyRiskMember2020-01-012020-06-300001704292us-gaap:CashAndCashEquivalentsMemberzlab:ForeignCurrencyRiskMember2019-01-012019-12-310001704292zlab:ResearchAndDevelopmentExpensesMemberus-gaap:SupplierConcentrationRiskMember2019-01-012019-06-300001704292us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2019-01-012019-06-300001704292us-gaap:CommonStockMember2020-06-300001704292us-gaap:CommonStockMember2019-12-310001704292us-gaap:CommonStockMember2019-06-300001704292us-gaap:CommonStockMember2018-12-3100017042922018-12-310001704292us-gaap:CashAndCashEquivalentsMemberzlab:ForeignCurrencyRiskMember2020-06-300001704292currency:USD2020-06-300001704292currency:HKD2020-06-300001704292currency:CNY2020-06-300001704292currency:AUD2020-06-300001704292us-gaap:CashAndCashEquivalentsMemberzlab:ForeignCurrencyRiskMember2019-12-310001704292currency:USD2019-12-310001704292currency:HKD2019-12-310001704292currency:CNY2019-12-310001704292currency:AUD2019-12-3100017042922019-06-300001704292zlab:NonVestedRestrictedSharesMember2020-01-012020-06-300001704292us-gaap:EmployeeStockOptionMember2020-01-012020-06-300001704292zlab:NonVestedRestrictedSharesMember2019-01-012019-12-310001704292us-gaap:EmployeeStockOptionMember2019-01-012019-12-310001704292country:CN2020-06-300001704292country:CN2019-12-310001704292zlab:NonVestedRestrictedSharesMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-06-300001704292zlab:NonVestedRestrictedSharesMemberus-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-06-300001704292us-gaap:EmployeeStockOptionMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-06-300001704292us-gaap:EmployeeStockOptionMemberus-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-06-300001704292zlab:NonVestedRestrictedSharesMember2020-01-012020-06-300001704292us-gaap:EmployeeStockOptionMember2020-01-012020-06-300001704292zlab:NonVestedRestrictedSharesMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2019-01-012019-06-300001704292zlab:NonVestedRestrictedSharesMemberus-gaap:ResearchAndDevelopmentExpenseMember2019-01-012019-06-300001704292us-gaap:EmployeeStockOptionMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2019-01-012019-06-300001704292us-gaap:EmployeeStockOptionMemberus-gaap:ResearchAndDevelopmentExpenseMember2019-01-012019-06-300001704292zlab:NonVestedRestrictedSharesMember2019-01-012019-06-300001704292us-gaap:EmployeeStockOptionMember2019-01-012019-06-300001704292us-gaap:AdditionalPaidInCapitalMember2020-01-012020-06-300001704292us-gaap:AdditionalPaidInCapitalMember2019-01-012019-06-3000017042922019-01-012019-06-3000017042922020-06-3000017042922019-12-31iso4217:USDxbrli:sharesiso4217:CNYiso4217:USDxbrli:sharesxbrli:purezlab:segmentzlab:Milestonezlab:leasezlab:item

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13A-16 OR 15D-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2020

Commission Filing Number: 001-38205

ZAI LAB LIMITED

(Translation of registrant’s name into English)

4560 Jinke Road, Bldg. 1, 4F, Pudong, Shanghai, China 201210

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

EXHIBIT INDEX

Exhibit No.

    

Description

23.1

Consent of Deloitte Touche Tohmatsu Certified Public Accountants LLP

99.1

Consolidated Financial Statements as of June 30, 2020 and for the six months ended June 30, 2019 (unaudited) and 2020

101.INS

Inline XBRL Instance Document - this instance document does not appear in the Interactive Data File because its XBRL tags are not embedded within the Inline XBRL document

101.SCH

Inline XBRL Taxonomy Extension Schema

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ZAI LAB LIMITED

By:

/s/ Billy Cho

Name:

Billy Cho

Title:

Chief Financial Officer

Date: September 11, 2020